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Microtubule-associated protein TauThe splicing of the microtubule-associated protein Tau is regulated during development and is found to be
deregulated in a growing number of pathological conditions such as myotonic dystrophy type I (DM1), in
which a reduced number of isoforms is expressed in the adult brain. DM1 is caused by a dynamic and unstable
CTG repeat expansion in theDMPK gene, resulting in an RNA bearing long CUG repeats (n N 50) that accumulates
in nuclear foci and sequesters CUG-binding splicing factors of the muscleblind-like (MBNL) family, involved in
the splicing of Tau pre-mRNA among others. However, the precise mechanism leading to Tau mis-splicing and
the role of MBNL splicing factors in this process are poorly understood. We therefore used new Tau minigenes
thatwe developed for this purpose to determine howMBNL1 andMBNL2 interact to regulate Tau exon 2 splicing.
We demonstrate that an intronic region 250 nucleotides downstream of Tau exon 2 contains cis-regulatory splicing
enhancers that are sensitive toMBNL and that bind directly toMBNL1. BothMBNL1 andMBNL2 act as enhancers of
Tau exon 2 inclusion. Intriguingly, the interaction ofMBNL1 andMBNL2 is required to fully reverse themis-splicing
of Tau exon 2 induced by the trans-dominant effect of long CUG repeats, similar to theDM1 condition. In conclusion,
bothMBNL1 andMBNL2 are involved in the regulation of Tau exon 2 splicing and themis-splicing of Tau in DM1 is
due to the combined inactivation of both.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Type 1 and type 2 myotonic dystrophy (DM1 and DM2) are rare
inheritedmultisystemic disorders induced by autosomal dominantmu-
tations corresponding to microsatellite expansions (CTG and CCTG in
DM1andDM2, respectively), which are responsible for a heterogeneous
and variable panel of clinical symptoms (reviewed in [1]). The deregu-
lation of alternative splicing is considered to be instrumental to theoy laboratory, Department of
y, Berkeley, CA 94720, USA.
Alzheimer & Tauopathies, Bât.
ce. Tel.: +33 320622073, +33
ant),
ights reserved.pathophysiology of myotonic dystrophies and could explain, at least to
some extent, the multisystemic effect of the mutations, since the splic-
ing pattern of multiple transcripts is modiﬁed in a variety of tissues
[2]. In particular, a deregulated alternative splicing of the transcript
encoding the microtubule-associated protein Tau has been observed
in several brain regions in both DM1 and DM2 patients. This, in turn,
is associated with the development of neuroﬁbrillary degeneration, char-
acterized by the aggregation of hyper- and abnormally-phosphorylated
isoforms of Tau, encountered in many neurodegenerative conditions
that together are called the Tauopathies [3–8].
In the human brain, Tau is mainly found in neurons and its principal
function is to stabilize the microtubule network, although other func-
tions in synaptic plasticity or the nucleus have been ascribed to it (for
review see [9]). Tau is encoded by a single gene, MAPT, containing 16
exons covering 140 kb at position q21 of chromosome 17. In the adult
human brain, six Tau isoforms are expressed by alternative splicing,
655C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–664resulting from the inclusion or not of exons 2, 3 and 10, whereas the
skipping of these exons is enhanced in DM brains, leading to the in-
creased expression of the fetal form of Tau [4, 6-8]. Tau mis-splicing
has also been reported in other pathologies, such as rare autosomal
dominant forms of frontotemporal dementia with Parkinsonism linked
toMAPTmutations, indicating a clear link between amodiﬁed Tau splic-
ing and neurodegeneration [10]. Understanding the pathological mech-
anisms leading to Tau mis-splicing could thus be crucial for the
development of novel therapeutic strategies for these diseases.
The MBNL family of regulatory splicing factors is composed of three
paralogs, MBNL1, MBNL2 and MBNL3, that are well conserved among
mammals [11]. The nucleocytoplasmic transport of mRNA is regulated
by MBNL1 and MBNL2 [12,13]. The pathophysiology of DM1 is princi-
pally based on the trans-dominant toxic effect of long CUG repeats
which induce a loss of MBNL function and/or a gain of function of mem-
bers of another regulatory-factor family, CELF [14–16]. The involvement
of these two families in the mis-splicing of Tau is supported by the fact
that both CELF2 overexpression andMBNL1 silencing enhance the skip-
ping of Tau exon 2, similar to that observed in the DM1 brain [7,17,18],
although the precise mechanisms underlying this reciprocal regulation
by MBNL and CELF family members, and in particular, how MBNL1
and MBNL2 precisely contribute to human Tau exon 2 splicing regula-
tion is poorly understood. In addition, in vivo studies of MBNL1 or
MBNL2 deﬁciency in mice have not all examined their effects on Tau
exon 2 splicing or even on the brain, and when they have done so,
have yielded discrepancies between the potential role of MBNL1 or
MBNL2 [19–21]. For instance, in the mouse brain, MBNL2 but notA
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Fig. 1. Characterization of the splicing pattern of the three new minigenes and localizat
representation of hTau minigenes: hTau 2Δ3, 878E2500 and 250E2250 were obtained by insertion
exon 1, 4 and partial intronic sequences into pEGFPN1 as described in theMaterials andMethod
sequences surrounding exons 2 and 3 in thehuman gene andminigenes is indicated aboveor be
which hTau was cloned. Arrows under the 250E2250 draft indicate the location of the primers (E
minigene transcripts from T98G cells co-transfected withminigenes and pcDNA (DT960−) or D
fection and RT-PCR for 18S rRNAwas used as an internal control. The graphs indicate the perce
Signiﬁcant differences determined by a parametric unpaired t-test are indicated by asterisks: *MBNL1 is suggested to be a strong regulator of the murin Tau exon 2
splicing, and the loss of MBNL2 expression promotes the skipping of
exon 2, mimicking to some extent the mechanism observed in DM1
[19]. In contrast, the loss of MBNL1 function in mice models heart and
muscle dysfunction in DM1, but no effect on Tau splicing has been re-
ported in this model [20,21]. Thus, although the target RNA sequence
for both factors is the YGCY motif [19,22,23] their effects on human
Tau exon 2 splicing are far from clear and need to be teased apart.
The expression and splicing activity of MBNL1 are both interrelated
and deregulated in DM1 [7,24,25], rendering any study of their activity
difﬁcult. In the present work, therefore, we used new minigene con-
structs derived from human MAPT to identify intronic cis-regulatory
regions essential for the splicing-enhancer function of MBNL1 and
MBNL2 with respect to Tau, and to demonstrate the direct binding of
MBNL1 to Tau pre-mRNA. Intriguingly, our results indicate that MBNL1
and MBNL2 act in concert to promote the rescue of Tau exon 2 in DM1,
with MBNL1 alone being insufﬁcient.
2. Materials and methods
2.1. Expression vectors
A novel reporter vector for splicing, hTau, was ﬁrst constructed by
the speciﬁc ampliﬁcation of the following human Tau sequence: exon
1, the ﬁrst 300 nucleotides of intron 1–2, the last 300 nucleotides of
intron 2–3 (i.e. omitting exon 2 entirely and the neighboring intronic re-
gions), and exon 4 (Fig. 1A), were yet synthesized by GeneArt® Gene43
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ion of intronic sequences required for the DM1 trans-dominant effect. A. Schematic
of the 2Δ3, 878E2500 and 250E2250 sequences into hTau, itself obtained by the insertion of
s. Top: an enlargement of the exon 1–4 region of theMAPT gene. The length of the intronic
low thedrafts. Interrupted bold lines represent the other parts of the peGFPN1 plasmid into
1, eGFP) used for the detection of hTauminigene-speciﬁc transcripts. B. Splicing pattern of
T960 (DT960 +). RT-PCR for the DMPK 3′UTR (DMPK) conﬁrmed the efﬁcacy of cell trans-
ntage of Tau exon 2 exclusion (mean ± SEM for at least three independent experiments).
: p b 0.05; **: p b 0.01.
Table 1
Primer sequences and PCR conditions for minigene constructions using InFusion system. In red: sequence corresponding to the host vector. In black: sequence corresponding to the
insert.
Minigene 
cloned
Sense primer Antisense primer
PCR 
conditions
Fragment 
size (pb)
hTau
5´ GGACTCAGATCTCGAGTGAAC
TTTGAACCAGGATGGCT 3´ 
5´ GGCGACCGGTGGATCATGCGA
GCTTGGGTCACG 3´ 
859 pb
2Δ3
hTau
5´ AAGGACACACGAATTGGAGCTG
TGCGCGGGACT 3´
3095 pb
878E2500
hTau
5´ AAAATAATTTGAATTGAATTC
TCAACCTTCCAGAGTG 3´ 5´ AAGGACACACGAATTAGATGC
CGAGTGTCTGG 3´
1495 pb
250E2250
hTau
5´ AAAATAATTTGAATTCTTTCA
CCCAGGAGCAAACGC 3´
5´ AAGGACACACGAATTCTTAAG
ACAGCACAGGGACTC 3´
22 cycles
607 pb
62 °C
656 C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–664Synthesis (Life Technologies Corp., Germany) and inserted into
a peGFP-N1 vector using InFusion® cloning system from Clontech.
Primers for the ampliﬁcation of this Tau fragment were designed
using online tools (http://www.clontech.com/) and are reported in
Table 1. PCR was carried out in a ﬁnal volume of 28 μL, with 10 pmoles
of each primer under the following conditions: 3 min at 94 °C, 22 cycles
of a 30-s denaturation step at 94 °C, annealing for 1 min at 62 °C, 1 min
of extension and 7 min at 72 °C for the ﬁnal extension. The PCR reaction
mix used was PCR Platinum Supermix High Fidelity (Invitrogen). Dpn1
enzyme, 0.5 μL (Invitrogen) was added to the PCR product, which was
incubated for 1 h at 37 °C before puriﬁcation using a Nucleospin Extract
II kit (Macherey-Nagel). The Tau fragment was then inserted into
pEGFP-N1 (Clontech, GenBankAccession#U55762) following lineariza-
tionwith EcoR1 (Invitrogen) for 1 h at 37 °C, and is hereafter referred to
as hTau. PCR ampliﬁcation and linearization of the plasmid were veri-
ﬁed on a 1% agarose gel, and bandswere stainedwith ethidiumbromide
(Invitrogen). cDNA and plasmid concentrations were determined by
measuring the absorbance at 260 nm using Nanodrop ND1000 technolo-
gy (Labtech, France).
hTau minigenes were constructed by inserting Tau exon 2
surrounded by intronic sequences of different sizes into the hTau vector
at the EcoR1 restriction site. In brief, using primers reported in Table 1,
we ampliﬁed three portions of theMAPT/Tau gene around exon 2: Tau 2
Δ3, 878E2500 and 250E2250. The Tau 2Δ3 fragment differed from the
endogenousMAPT gene by a truncation of introns 1–2 and 2–3: the se-
quence of intron 1–2 was limited to the last 878 nucleotides (instead of
9388) and the sequence of the intron 2–3 to the ﬁrst 2092 nucleotides
(instead of 2439) (Fig. 1A). The Tau 878E2500 fragment differed from
Tau 2Δ3 by the limitation of the intronic sequence downstream of
exon 2 to the ﬁrst 500 nucleotides of intron 2–3. The Tau 250E2250 frag-
ment contained the last 250 nucleotides of intron 1–2 and the ﬁrst 250
nucleotides of intron 2–3. The ampliﬁcation products for the construc-
tion of all three hTau minigenes were inserted into the hTau vector
after EcoR1 cleavage using an insert/vector ratio of 2/3, with InFusion®
technology (Clontech), by ﬁrst incubating at 37 °C for 15 min and then
at 50 °C for an additional 15 min. The reactionmixture was then placed
on ice and 40 μL of sterile H2O added. Transformation was carried out
using Top10 bacteria grown in LB added with kanamycine 50 μg/μL
medium for plasmid production.
In addition, depending on the experiment, we used other plasmids.
The DT960 plasmid (kind gift of Dr T. Cooper), containing 960 interrupted
CTG repeats, was used tomimic the DM1mutation [26]. A full-length V5-
tagged MBNL1 plasmid has been previously described in Dhaenens et al.
[7]. TheGFP-taggedMBNL2plasmidwas kindly provided byDr. J.D. Brook
[11]. All vector sequences were veriﬁed by double-stranded sequencing
(GATC Biotech, Constance, Germany). Plasmid DNAs were puriﬁed
using Nucleobond AX (Macherey- Nagel, Dûren, Germany). In addition,
in certain experiments, the Tau 2Δ3 fragment was mutated at MBNL-responsive sites by GeneArt® Gene Synthesis technology (Life technol-
ogies Corp.). Two mutants (Mut9 and Mut16) that differed in terms of
the number and localization of mutations were used.
2.2. Cell culture and transfection
The human glioblastoma T98G cell line was maintained in DMEM
medium supplemented with 10% fetal calf serum, 50 IU/mL penicillin,
50 mg/mL streptomycin and 4 mmol/L glutamine. Assays for geneover-
expression were performed using FuGENE® HD transfection reagent
(Promega). For multiple transfections, the empty pcDNA3.1 vector
was used as a control and was added in order to have the same DNA
concentration under each condition. Transfections were performed
using a ratio of 1 μg of plasmids for 3 μL of FuGENE® HD. Thus, 1 μg of
each plasmid (Minigene/pcDNA3.1/DT960/Splicing factor) was mixed
with 6, 9 or 12 μL of FuGENE® HD reagent according to the transfection
condition (double, triple, quadruple), in 100 μL of OPTIMEM medium
(Invitrogen). After an incubation of 20 min at room temperature, the
mix was added to the culture medium. Total RNA was extracted 24 h
later using Nucleospin RNA II kit (Macherey- Nagel, Dûren, Germany).
For MBNL1 RNA silencing, we used ON-TARGETplus SMARTpool
siRNAs and a non-targeting SMARTpool (ThermoScientiﬁcBio). The
MBNL1 SMARTpool contains a mixture of 4 modiﬁed oligonucleotides
complementary to the human MBNL1 mRNA. The targeted sequences
were: 5′CAUAAUAUCUGCCGAACAU3′, 5′GGCCAGACACGGAAUGUAA3′,
5′GAAAUGAUUGUCGGUUUG3′ and 5′ACAAGUAUGUUACCCAGAU3′.
For siRNA transfection, T98G cells were plated in 12-well plates and
incubated at 37 °C with 5% CO2 overnight. Transfection was achieved
by adding siRNA (25 nM) using DharmaFECT 1 transfection reagent
(ThermoScientiﬁcBio) according to the manufacturer's instructions.
Transfected cells were incubated at 37 °C in 5% CO2 for 24 additional
hours. The medium was removed and minigenes were transfected
using FuGENE® HD transfection reagent (Promega) following the
above protocol. Total RNA was extracted 24 h later. For controls, we
transfected ON-TARGET siRNA plus non-targeting pool according to
the manufacturer's instructions (ThermoScientiﬁcBio).
2.3. RNA extraction, RT-PCR and semi-quantitative analysis
Total RNA was isolated from cells using a total RNA extraction kit
(Nucleospin® RNA II kit, Macherey-Nagel). RNA concentrations were
determined by measuring the absorbance at 260 nm using Nanodrop
ND1000 technology (Labtech, France). RT-PCR was performed in three
independent experiments. A total of 1.5 μg of total RNA was reverse
transcribed using random hexamers (5 μM) and M-MLV reverse tran-
scriptase (Invitrogen, California, USA), according to standard protocols.
PCR was carried out in a ﬁnal volume of 10 μL with 10 pmoles of each
primer (primer sequences and ampliﬁcation conditions are detailed in
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Fig. 2. Localization of intronic sequences needed for exon 2 splicing regulation byMBNL1. T98G cells were ﬁrst transfectedwithMBNL1 siRNA (+) or control siRNA (−) for 24 h, then
transfected with the three minigenes with (+) or without (−) DT960, as indicated in the Materials and Methods. A. Transfection with WT hTau 2Δ3 (hTau). B. Transfection with hTau
878E2500. C. Transfection with hTau 250E2250. Note that exon 2 skipping is enhanced in transcripts from the threeminigenes in the presence of MBNL1 siRNA.MBNL1 siRNA did notmodify
theCUG effect. RT-PCR for theDMPK3′UTR (DMPK) andMBNL1 conﬁrmed the efﬁcacy of cell transfection and RT-PCR for 18S rRNAwas used as an internal control. The graphs indicate the
percentage of Tau exon 2 exclusion (mean ± SEM for at least three independent experiments). Signiﬁcant differences determined by a parametric unpaired t-test are indicated by aster-
isks: *: p b 0.05; **: p b 0.01; ***: p b 0.001; ****: p b 0.0001; ns: non-signiﬁcant.
657C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–664Table 2), 5 μL of GoTaq® GreenMasterMix (Promega) and 1 μL of cDNA
under the following conditions: 3 min at 94 °C, 17 to 32 cycles of a 30-s
denaturation step at 94 °C, annealing for 1 min at sequence-speciﬁc tem-
peratures (Table 2), 1 min of extension and 7 min of ﬁnal extension at
72 °C. 18S rRNA was used as an internal loading control. Reaction prod-
ucts were resolved by electrophoresis using a 2% or 3% agarose gel and
bands detected by staining with ethidium bromide (Invitrogen). No
DNA ampliﬁcation was observed in PCR controls in the absence of
cDNA. Images were acquired using a Molecular Imager ® Gel Doc™ XR
System (Bio-Rad, USA), and the ampliﬁed bands quantiﬁed using Image
J image analysis software [27].2.4. Electrophoretic mobility shift assays
RNAwas synthesized by the in vitro transcription of a PCR fragment
of 392 nucleotides corresponding to the wild-type (WT) 2Δ3 region
(from 103 nucleotides 5′ to Tau exon 2 to 202 nucleotides of intron
2–3) of Tau pre-mRNA, using T7 RNA polymerase. After gel puriﬁcation,
the RNA was dephosphorylated with calf intestinal phosphatase (NEB)
and 5′ end-labeled using [γ-32P]-ATP (3000 Ci mmol−1) and T4 poly-
nucleotide kinase (NEB). Labeled RNA was then puriﬁed using mini
QuickSpin RNA columns (Roche). For complex formation, about 2 nmol
of 5′ end-labeled RNA was preincubated in 7 μL of buffer D (150 mM
KCl, 4.5 mM MgCl2, 20 mM HEPES pH 7.9, 10% glycerol) for 10 min atTable 2
Primer sequences and PCR conditions for ampliﬁcation of speciﬁc transcripts.
Sequence ampliﬁed Sense primer Antisense
MBNL1 5′ ATTACAACCCGTGCCAATGT 3′ 5′ CAGCC
MBNL2 5′ CTTCATCCAGTGCCCACTTT 3′ 5′ TGGAA
hTauE2 insert 5′ GGGGACAGGAAAGATCAGG 3′ 5′ GCTGA
Endogenous
Tau: exon 1/4
5′ TACGGGTTGGGGGACAGGAAAGAT 3′ 5′ GGGGT
DMPK 3′UTR 5′ GGGGATCAACAGACCATTTCTT 3′ 5′ CACTT
18S 5′ AAACGGCTACCACATCCAAG 3′ 5′ CGCTC65 °C in the presence of 2 μg of tRNA, followed by slow cooling. Then,
4 μL of MBNL1Δ101 recombinant protein, puriﬁed as detailed in [24],
was added to the renatured RNA to a ﬁnal protein concentration ranging
from 0 to 3.2 μM. The binding reactions were incubated for 30 min at
room temperature and loaded onto a non-denaturing 5% (38/2) poly-
acrylamide gel containing 1 mM EDTA, 44.5 mM Tris borate, pH 8.3,
and 5% glycerol. Gels were run at 4 °C and 10 V cm−1. The amount of ra-
dioactivity in the bands, corresponding to free and bound RNAs, was esti-
mated using a Storm PhosphorImager and ImageQuant software. From
these values, apparent Kd values were determined using Microsoft Excel.2.5. Fluorescent in Situ Hybridization (FISH) and MBNL localization
T98G cells were plated onto Lab-Tek chamber slides coated with
poly-D-lysine (5 mg/cm2; Sigma). On the following day, T98G cells
were transiently transfected with a total of 3 μg of DNA, containing
1 μg of one of the following plasmids: V5-MBNL1 or/and eGFP-MBNL2
and DT960 or not, using the transfection reagent FuGENE®HD (Promega)
according to the manufacturer's instructions. After 24 h, cells were ﬁxed
in 4% paraformaldehyde in 0.1 M phosphate buffered saline (PBS) for
20 min at room temperature. Cells were washed three times with
0.1 M phosphate buffered saline (PBS). FISHwas performed as described
using a Cy3-labeled nucleic acid (CAG)7 probe [24]. After washing, cells
were permeabilized with 0.25% Triton X-100 in PBS. After blocking withprimer PCR conditions Fragment size (pb)
TGGTTGACCTGGTAT 3′ 60 °C,
20 cycles
440
CTCCCTGCATACCTC 3′ 60 °C,
20 cycles
230
ACTTGTGGCCGTTTA 3′ 60 °C,
30 cycles
2−: 256
2+: 343
GTCTCCAATGCCCTGCTTCT 3′ 60 °C,
32 cycles
2− 3−: 112
2+ 3−: 199,
2+ 3+: 286
TGCGAACCAACGATA 3′ 56 °C,
25 cycles
171
CCAAGATCCAACTAC 3′ 58 °C,
17 cycles
250
658 C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–6641% bovine serum albumin (BSA) in PBS, the ﬁxed cells were incubated
overnight at 4 °C with the primary antibody in PBS with 1% BSA and
0.25% Triton X-100. Anti-V5 (Millipore, 1/10,000) and anti-GFP antibod-
ies (SantaCruz, 1/200) were used to detect MBNL1 and MBNL2 proteins,
respectively. After washing, cells were incubated with Alexa Fluor®
conjugated secondary antibodies (Invitrogen). Nucleic acidswere stained
using TOPRO®-3 for 30 min at 37 °C. Slides were coverslipped with
Vectashield (Vector laboratories). Images were captured using a Leica
confocal microscope and software (Leica Microsystems) and processed
with Adobe Photoshop Element 9 software.
2.6. Statistical analysis
Statistical analyses were performed using a parametric unpaired
Student's t-test or analysis of variance (ANOVA) using Prism 6 Software
(GraphPad Software Inc., San Diego, USA). Graphswere generated using
GraphPad.
3. Results
3.1. Development of novel human Tau minigenes for the study of exon 2
splicing
To study Tau exon 2 splicing, we generated a novel vector derived
from human Tau (hTau), containing constitutively expressed Tau
exons 1 and 4 followed or preceded by a 300 nucleotide intronic se-
quence (Fig. 1A). In this vector, we inserted Tau exon 2 ﬂanked by 878
or 250 nucleotides of intron 1–2, and 2092, 500 or 250 nucleotides of
intron 2–3, respectively, to generate three hTau minigenes. These
minigenes were transfected into the human glioblastoma T98G cell
line, which is known to express endogenous Tau protein isoforms
with a splicing pattern similar to that observed in the adult human
brain [5,28]. All three minigenes allowed the alternative splicing of
Tau exon 2 to be observed in this cell system. The rate of Tau exon 2
skipping increased with the size of the insert, from 4% in hTau
250E2250 to 9% in hTau 878E2500 and 21% in 2Δ3 (in which the size of
the inserted sequence upstream of exon 2 was the same as in 878E2500,
but the size of the downstream sequence increased to 2092nucleotides;
Fig. 1B), suggesting that there is a strong cis-regulatory repressive ele-
ment 500 nucleotides downstream of Tau exon 2. Using these hTau
minigenes, we next investigated the trans-dominant repressive effect
of RNAs containing long CUG repeats by co-transfecting T98G cells
with hTau minigenes as well as the DT960 plasmid, which contains 960
CTG repeats (CTG960). Indeed, the skipping of Tau exon2was signiﬁcantly
shifted in all threeminigenes in the presence of CUG960, from 4 to 23% for
hTau250E2250, 9 to 21% for 878E2500 and 24 to 52% for 2Δ3 (Fig. 1B). Taken
together, our results suggest that the CUG960-responsive elements are
likely located in the intronic sequence proximal to Tau exon 2. Notably,
these 250-nucleotide intronic sequences ﬂanking exon 2 contains both
potential CELF2- and MBNL-binding sites, consistent with a role of these
splicing factors in mediating the mis-splicing of Tau exon 2 in the pres-
ence of CUG repeats (Fig. 3, Supplementary Fig. 1). In addition, the near
absence of CELF1 sites in this region is in agreement with the previously
observed absence of a CELF1 effect on Tau exon 2 splicing [18] (Supple-
mentary Fig. 1 and data not shown).
3.2. Tau exon 2 skipping is promoted by MBNL1 loss of expression
The contribution of MBNL family members to Tau exon 2 splicing
was investigated next. The loss of MBNL1 expression is supposed to
model many of the trans-dominant effects of CUG repeats, we ﬁrst
silenced endogenousMBNL1 expression using a pool of speciﬁc siRNAs.
T98G cells were ﬁrst transfected with the siRNA pool for 24 h, before
transfection with hTau minigenes. Altogether, after 48 h post-
transfection, endogenous MBNL1 expression levels were reduced
by 80% on average for all three minigene experimental conditions(Fig. 2). This loss of MBNL1 expression signiﬁcantly promoted Tau
exon 2 skipping, regardless of the hTau minigene in which MBNL1
was silenced (Fig. 2A,B,C), suggesting that intronic cis-regulatory ele-
ments sensitive to both CUG repeats and the loss of MBNL1 expression
are present immediately in close vicinity of Tau exon 2 (Fig. 2A–C). We
next assessed the effect of the presence of CUG repeats concomitant
with the loss of MBNL1 expression. Tau exon 2 skipping was further
promoted by DT960 expression, even when MBNL1 expression was re-
pressed by siRNA (Fig. 2A–C). Together, our results indicate that Tau
exon 2 splicing is regulated byMBNL, and that both regulatory elements
recruited by the trans-dominant effect of CUG repeats and those recruit-
ed by the MBNL1 loss-of-expression are located within the 250 nucleo-
tide intronic region immediately proximal to the Tau exon 2. However,
DT960 had a more pronounced effect than MBNL1 silencing alone, espe-
cially with regard to 2Δ3 and 250E2250, suggesting a partial effect due to
residual MBNL1 expression (20%) or possibly due to the contribution of
other undetermined regulatory mechanisms.
To conﬁrm whether MBNL-responsive cis-regulatory elements on
Tau RNA are targeted or not by the trans-dominant effect of CUG
repeats, we next mutated all putative MBNL1-responsive elements
within 250 nucleotides on either side of exon 2. These consisted of 16
YGCY motifs, of which 13 were UGCU and the three others were CGCU
or UGCC (Fig. 3). Two were located upstream of exon 2, one within
exon 2, and the rest downstream of exon 2 (Fig. 3). With the help of
the SpliceAID online application [29], we determined deletions, G-to-A
substitutions or other potent mutations that would in theory abolish
MBNL1-binding sites without creating or deleting other potential cis-
regulatory RNA sequences (Fig. 3). These mutations of MBNL1 target el-
ements were made to the longest hTau minigene, 2Δ3. Two mutant
minigenes were obtained: Mut16, in which all 16 potential MBNL-
responsive elements were mutated, and Mut9, in which 10 out of the
13 putative MBNL-binding sites downstream of exon 2 were mutated,
leaving the most proximal ones potentially functional (Fig. 3). At base-
line, the rate of Tau exon 2 skipping was signiﬁcantly and comparably
elevated in both mutated minigenes (Mut9: 37%; Mut16: 37%) when
compared to WT hTau 2Δ3 (14%) (Fig. 4A). In the presence of siRNA
to abolish MBNL1 expression, the rate of Tau exon 2 skipping while
using these mutated minigenes remained unchanged, unlike results
obtained with theWTminigene, conﬁrming that the effect of themuta-
tions on Tau splicing is most likely related to the loss of MBNL1 activity.
Furthermore, these mutations did not induce any additional effect of
trans-dominant CUG repeats (i.e. in the presence of DT960) since the
splicing pattern of exon 2 observed with Mut9 (53% exclusion) and
Mut16 (47% exclusion) was quite similar to those observed with the
WT transcript (52%), indicating that the effects of these mutations on
exon 2 splicingwere not independent of those of CUG repeats. However,
the residual effect of CUG repeats on exon 2 skipping in Mut9 (37% vs.
53% in the presence and absence of CUG repeats, respectively) and
Mut16 minigenes (36 vs. 47% in presence and absence of CUG repeats,
respectively), combined with the lack of an effect of siRNA to MBNL1
on exon 2 splicing in the presence of DT960, suggests that part of the
CUG effect is mediated by other sequences that are unmutated and
non-MBNL1-dependent (Fig. 4A). As expected given these results, i.e.
that the effects of MBNL1 binding are not independent of those of
trans-dominant CUG repeats, but that the effects of CUG repeats are par-
tially independent of those of MBNL1 binding, the presence of siRNA to
MBNL1 did not have any incremental effect on the increase in exon 2
skipping induced by CUG repeats.
In order to conﬁrm that the mutated sites were those principally
necessary for MBNL1 binding, an electrophoretic mobility shift assay
was performed by incubating GST-MBNL1Δ101, a soluble form of
MBNL1, with Tau pre-mRNA fragments produced in vitro from the WT,
Mut16 andMut9minigenes. Fig. 4B shows that theMBNL1Δ101 recom-
binant protein bound to Tau pre-mRNA in vitro with an apparent Kd of
0.7 μM, and that, at least two andpossibly threemutated siteswere like-
ly to bind to MBNL. Mutations in these MBNL-binding sites resulted in
Tau exon 2
WT
CTTTCACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCC
TGGTGTGGGGCACAGTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCC
TTTGTGGGTTTGTTGCGAGGCCGTGTTCCAGCTGTTTCCACAGGGAGCGA
TTTTCAGCTCCACAGGACACTGCTCCCCAGTTCCTCCTGAGAACAAAAGG
GGGCGCTGGGGAGAGGCCACCGTTCTGAGGGCTCACTGTATGTGTTCCAG
AATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTG
AAACCTCTGATGCTAAGAGCACTCCAACAGCGGAAG
GTGGGCCCCCCTTCAGACGCCCCCTCCATGCCTCCAGCCTGTACTTAGCC
ΔTACTTTGAGCCTCCCTCCTGGCTGCATCTACΔGCTCCCCCTGGCTGAGAGA
TΔΔΔΔTCACTCCTTCGGTACTΔΔΔΔCAGGACAGCGTGGTGGGAGCTGAG
CCTTΔΔΔΔCGATΔΔΔTAΔΔCTTACTGGTΔΔTGAGTGTGGGCACCTTCATCC
CGTGTGTGCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCC
CTTTCACCCAGGAGCAAACGCACATCACCTGTGTCCTCATCTGATGGCCC
TGGTGTGGGGCACAGTCGTGTTGGCAGGGAGGGAGGTGGGGTTGGTCCCC
TTTGTGGGTTTGTTGCGAGGCCGTGTTCCAGCTGTTTCCACAGGGAGCGA
TTTTCAGCTCCACAGGACACAGCTCCCCAGTTCCTCCTGAGAACAAAAGG
GGGTTCTGGGGAGAGGCCACCGTTCTGAGGGCTCACTGTATGTGTTCCAG
AATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTG
AAACCTCTGACCGTAAGAGCACTCCAACAGCGGAAG
GTGGGCCCCCCTTCAGACGGCCCCTCCATCGCTCCAGCCTGTACTTAGCC
ΔTACTTTGAGCCTCCCTCCTGGCTGCATCTCGGGCTCCCCCTGGCTGAGAGA
TGΔΔΔΔTCACTCCTTCGGTACTΔΔΔΔCAGGACAGCGTGGTGGGAGCTGAG
CCTTΔΔΔΔCGATΔΔΔTAΔΔCTTACTGGTΔΔTGAGTGTGGGCACCTTCATCC
CGTGTGΔGCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCC
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Tau exon 2
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-50
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TTTGTGGGTTTGTTGCGAGGCCGTGTTCCAGCTGTTTCCACAGGGAGCGA
TTTTCAGCTCCACAGGACACTGCTCCCCAGTTCCTCCTGAGAACAAAAGG
GGGCGCTGGGGAGAGGCCACCGTTCTGAGGGCTCACTGTATGTGTTCCAG
AATCTCCCCTGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTG
AAACCTCTGATGCTAAGAGCACTCCAACAGCGGAAG
GTGGGCCCCCCTTCAGACGCCCCCTCCATGCCTCCAGCCTGTGCTTAGCC
GTGCTTTGAGCCTCCCTCCTGGCTGCATCTGCTGCTCCCCCTGGCTGAGA
GATGTGCTCACTCCTTCGGTGCTTTGCAGGACAGCGTGGTGGGAGCTGAG
CCTTGCGTCGATGCCTTGCTTGCTGGTGCTGAGTGTGGGCACCTTCATCC
CGTGTGTGCTCTGGAGGCAGCCACCCTTGGACAGTCCCGCGCACAGCTCC
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Fig. 3. Localization of putative MBNL sites (A) and mutations of MBNL sites (B, C) in the Tau exon 2 region. As determined using SpliceAids, putative MBNL-binding sites in the Tau
exon 2 sequence (WT) from 250 nucleotides upstream to exon 2 to 250 nucleotides downstream are indicated in green. In bold green letters: putative strong YGCY MBNL-binding sites.
The exon 2 sequence is underlined in grey. Mutations by substitution are indicated in red letters. Deletions of nucleotides are indicated by Δ symbols.
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tants (Mut16 Kd: 1.4 μM; Mut9 Kd: 2 μM).
3.3. MBNL rescue activity
MBNL1 overexpression restores the splicing of several exons to
normal levels, thus compensating for the loss of MBNL1 function
[30,31]. In the present study, when co-transfected with the WT hTau
2Δ3, ectopic MBNL1 expression promoted Tau exon 2 inclusion (i.e. re-
duced its exclusion, Fig. 5A and B), whereas mutation of the predicted
MBNL-binding sites attenuated this effect. Surprisingly, the ectopic
expression of MBNL1 did not restore the exon 2 skipping induced by
DT960 (Fig. 5A and B).
Since MBNL1 overexpression was insufﬁcient to restore exon 2
splicing in the presence of DT960, we hypothesized that MBNL2 could
be an alternative candidate to reverse the trans-dominant effect of
CUG960. Unlike MBNL1, MBNL2 overexpression did not promote Tau
exon 2 inclusion in WT hTau 2Δ3 in the absence of DT960 (Fig. 5C,D).In sharp contrast, when co-expressed with the DT960 vector, MBNL2 re-
pressed the skipping of Tau exon 2 induced by CUG repeats (Fig. 5C and
D). To conﬁrm the speciﬁcity of this process, we determined whether
this rescuing activity of MBNL2 was abolished when MBNL-binding
sites were mutated (Fig. 5C and D). The rescue effect was attenuated
with both Mut9 and Mut16 minigenes, showing that MBNL2 but not
MBNL1 remedied the defective splicing of Tau exon 2 in T98G cells
expressing the DM1 mutation.
3.4. MBNL1 and MBNL2 act synergistically to repress the skipping of Tau
exon 2 induced by CUG960 expression
Several mechanisms could explain the beneﬁcial effect of ectopic
MBNL2 expression in the presence of a trans-dominant DM1 mutation.
The ﬁrst explanation is that the overexpression of MBNL2 could titrate
the effect of CUG960. However, this explanation, based on the amount
of MBNL protein, is not completely satisfactory since a rescue effect
would also be observed with the ectopic expression of MBNL1 alone.
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the trans-dominant effect of CUG960 repeats on Tau exon 2 splicing,
through a non-competitive mechanism. We tested this last hypothesis
using two experimental protocols: 1) the overexpression of both
MBNL1 and MBNL2 (Fig. 6A), and 2) the overexpression of MBNL2
and the silencing of MBNL1 in T98G cells (Fig. 6B).
In agreement with previous experiments (Fig. 5), the co-expression
of DT960 with MBNL1 did not signiﬁcantly reduce the skipping of Tau
exon 2 whereas ectopic MBNL2 expression did (Fig. 6A). Interestingly,
however, the co-expression of both MBNL1 and MBNL2 rescued the
splicing defect induced byDT960 expression to a signiﬁcantly greater ex-
tent than MBNL2 alone (DT960: 50%; MBNL1 + MBNL2: 29%, p b 0.01),
MBNL2: 39%, p b 0.05 (Fig. 6A).
Since the rescuing activity of MBNL2 was enhanced when MBNL1
was concomitantly expressed, we next hypothesized that the silencing
of endogenous MBNL1 expression would impede MBNL2-mediated
rescue (Fig. 6B). To assess this hypothesis, MBNL1 expression was ﬁrst
silenced with a siRNA pool for 24 h, and cells were then transfected
with MBNL2 in the absence or presence of DT960. Similar to results
shown in Fig. 2A, the silencing of MBNL1 led to a signiﬁcant elevation
of Tau exon 2 exclusion from 18% to 43% (p b 0.001, Fig. 6B). As seen
earlier (Fig. 5C and D), Tau exon 2 inclusion was not signiﬁcantly
enhanced by the ectopic expression of MBNL2 alone. Furthermore,
MBNL2 overexpression prevented the increase in exon 2 skippinginduced by MBNL1 silencing (18% in control condition; 43% when
MBNL1 was silenced; 21% in siMBNL1 + MBNL2 co-transfected cells;)
(Fig. 6B), demonstrating that the effect of MBNL1 loss-of-function on
exon 2 inclusion could be compensated for by MBNL2. In the DM1 con-
dition, however (i.e. in the presence of DT960),MBNL2was only partially
effective at reducing themis-splicing of Tau exon 2 induced by the con-
comitant presence of CUG repeats and silencing of MBNL1 expression
(Fig. 6B). Indeed, Tau exon 2 exclusion was diminished by 22% when
T98G cells were co-transfected with DT960 and MBNL2 (61% with
DT960 vs. 39% with DT960 + MBNL2, p b 0.001, Fig. 6B) whereas this
reduction dropped to 8% when MBNL1 expression was silenced before
co-transfection of MBNL2-overexpressing cells with DT960 (61% with
siMBNL1 + DT960 vs. 53% with siMBNL1 + DT960 + MBNL2, p b 0.01,
Fig. 6B). These results suggest that 1) MBNL2 alone cannot compensate
for the loss of MBNL1 expression in the presence of CUG, and 2) the res-
cue of Tau mis-splicing by MBNL2 could in part require endogenous
MBNL1, although endogenous or overexpressed MBNL1 alone cannot
prevent the exon 2 skipping induced by CUG repeats. Alternatively,
the effect could also be explained by the selective binding of MBNL1
orMBNL2 to certain foci. In order to address this hypothesis,we checked
the ability of MBNL1 and MBNL2 to colocalize in foci in our cell system
(Fig. 6C). Both MBNL1 and MBNL2 were colocalized in nuclear foci
with no particular differences that could explain the difference in splic-
ing regulation between them.
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The present work provides novel insights into the regulation of the
alternative splicing of Tau exon 2 by members of the MBNL splicing-
factor family. We have demonstrated here that the DM1-related defec-
tive splicing of Tau exon 2 involves MBNL-responsive proximal cis-
regulatory intronic elements. Interestingly, our results suggest that
the rescue of the trans-dominant effect of the DM1 mutation (i.e. the
presence of CUG repeats) on Tau exon 2 mis-splicing necessitates the
coordinated action of both MBNL1 and MBNL2, whereas MBNL2 or
MBNL1 alone has little or no rescue activity.
4.1. Splicing-enhancer activity of MBNL proteins with regard to Tau exon 2
To decipher the mechanism of exon 2 splicing regulation by MBNL
proteins, we generated hTau minigenes derived from the human
MAPT gene. These new splicing reporter tools have allowed us to iden-
tify the intronic cis-regulatory elements responsive both to MBNL1 si-
lencing and the DM1 mutation within 250 nucleotides proximal to
exon 2. Mutations of the potential MBNL-binding sites in these se-
quences have further demonstrated the role of MBNL in enhancing
Tau splicing. First, the basal rate of Tau exon 2 skipping is enhanced inboth mutated hTau minigenes when compared to the WT minigene.
Secondly, the effects of these mutations on exon 2 skipping are not ad-
ditive to those induced byCUG repeats, suggesting that the effect of CUG
repeats is mediated, at least in part, by MBNL1 sequestration and the
subsequent loss of its activity. The mutations downstream of exon 2
seem to be essential for MBNL activity since the basal level of exon 2
skipping is comparable in both Mut9 and Mut16 mutants, which share
these mutated downstream MBNL1-binding sites. In addition, the
MBNL binding sites downstream of Tau exon 2 are conserved between
species (as revealed by a comparison with the murine Mapt gene),
but not those upstream of exon 2. In agreement with Goer's model,
these downstream MBNL-binding YGCY motifs correspond to intronic
splicing-enhancer motifs, to which the binding of MBNL would promote
Tau exon 2 inclusion [32]. Indeed, when considering Tau splicing,
MBNL1 has such a regulatory splicing-enhancer activity since both the
silencing ofMBNL1 and themutation of its binding sites induce increased
exon 2 skipping. Furthermore, the effects of binding-site mutations and
electrophoretic mobility shift assays argue for a direct regulatory role of
MBNL on exon 2 splicing.
All thesemutations of sites proximal to exon 2 are, however, insufﬁ-
cient to fully reproduce the skipping pattern induced by CUG repeats,
since signiﬁcant residual CUG activity can be observed with mutant
%
 E
2 
ex
cl
us
io
n 
%
 E
2 
ex
cl
us
io
n 
hTau 2Δ3
DMPK
MBNL1
18S
MBNL2
MBNL1
DT960
+ +
- ---
- -
A
MBNL2 - +- +
+ +
+ +++
- -
- +- +
2+
2-
***
ns
ns*
**
MBNL1
MBNL2
DMPK
18S
hTau 2Δ3
B
2+
2-
siMBNL1
DT960
+ +
+ +--
- -
MBNL2 - -- -
+ +
+ +--
- -
+ ++ +
***
ns
***
ns
**
***
70
60
50
40
30
20
10
0
70
60
50
40
30
20
10
0
MBNL1 
MBNL2 
DT960
Merged FISH MBNL2 MBNL1
MBNL1 
DT960
MBNL2 
DT960
20 µm
pcDNA 
DT960
MBNL1
C Merge
d
FISHMBNL
MBNL2
MBNL1 MBNL2
20 µm
20 µm
20 µm
*** ***
Fig. 6. Combined rescue effect of MBNL1 and MBNL2 with respect to the Tau exon 2 mis-splicing induced by DT960. The WT hTau 2Δ3 minigene was used in this assay. A. Effect of
MBNL1 overexpression on MBNL2 rescue activity. Minigenes were co-transfected with (+) or without (−) MBNL1, MBNL2 and DT960. Note that MBNL1 overexpression enhanced
MBNL2 rescue activity. B. Co-transfection of minigenes with (+) or without (−) MBNL2 and DT960 after the silencing of endogenous MBNL1 expression. Note that MBNL2 corrected
the splicing alteration due toMBNL1 silencing but thatMBNL1 silencing decreasedMBNL2 rescue activity. RT-PCR for theDMPK 3′UTR (DMPK), MBNL1 andMBNL2 conﬁrmed the efﬁcacy
of cell transfection and RT-PCR for 18S rRNA was used as an internal control. The graph indicates the percentage of Tau exon 2 exclusion (mean ± SEM for at least three independent
experiments). Determined by a two-way ANOVA, signiﬁcant differences are indicated by asterisks: *: p b 0.05; **: p b 0.01, ***: p b 0.001; ns: non-signiﬁcant. C. Co-localization of both
MBNL1 and MBNL2 in foci. FISH and immunochemistry were performed on cells transfected with DT960 in the absence or presence of the overexpression of MBNL1, MBNL2 or both.
See Materials and Methods for detailed experimental protocol.
662 C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–664transcripts. Thus, it is possible that other regulatory elements are re-
cruited for the trans-dominant CUG effect on Tau exon 2 skipping.
These could be related either to the involvement of other factors such
as CELF2 [17,18] or the existence of other cis-regulatory sites at more
distal locations, corresponding to MBNL-binding sites or binding sitesfor other factors. Indeed, with regard to MBNL, we cannot completely
exclude the possibility that other YGCYmotifs located inmore distal re-
gions of intron 2–3 could contribute to the trans-dominant effect of the
DM1 mutation, since mutations of MBNL-binding sites in our study
were carried out using the hTau 2Δ3 minigene that allows exon 2
663C. Carpentier et al. / Biochimica et Biophysica Acta 1842 (2014) 654–664splicing to be reproduced with a pattern comparable to that of the en-
dogenous MAPT gene in contrast to 250E2250 minigene. In addition to
themediation of MBNL's splicing-enhancer activity by these sequences,
our results also conﬁrm the existence of an intronic splicing-inhibitor
sequence between 500 and 2100 nucleotides downstream of exon 2,
in agreementwith the results of the Andreadis group [33]. Since themu-
tated MBNL binding sites are located within around 250 nucleotides of
exon 2, we cannot rule out the potential contribution of this distal re-
pressive element, since distal intronic elements playing a role in splicing
regulation have been previously reported in the literature [34,35].
A cis-regulatory enhancer element or factor is often demonstrated
following the overexpression and/or repression of a trans-regulatory
factor. Surprisingly, the overexpression of MBNL1 or MBNL2 or both
did not strongly enhance exon 2 inclusion. This regulatory mechanism
is peculiar to Tau splicing itself or to cell-type since the overexpression
of MBNL1 in other cell types promotes exon inclusion in both IR and
Bin-1 [24,36–38]. It is, indeed, important to note that these results
were observed in T98G cells, which principally express MBNL1. Thus,
the demonstration that bothMBNL 1 andMBNL2 are Tau exon 2 splicing
enhancers relies on the silencing of MBNL and the mutation of MBNL-
binding sites. Under both conditions, Tau exon 2 skipping is enhanced,
demonstrating an attenuation of the enhancer activity of MBNL. This is
consistent with what is observed in the brain, in which both MBNL1
and MBNL2 are expressed, suggesting that the trans-dominant effect
of CUG repeats depends on the loss of function of both MBNL1 and
MBNL2.4.2. MBNL rescue activity
In accordancewith the essential role ofMBNL1 inDM1-inducedmis-
splicing, the overexpression of MBNL1 is able to rescue the effect of the
DM1 mutation, as demonstrated for multiple transcripts in several sys-
tems [30,31,39]. Surprisingly, in our cell system, the overexpression of
MBNL1, up to 10-times its normal levels, concomitantly with DT960,
does not reverse Tau exon 2 skipping. However, the ectopic expression
of MBNL2, which in fact reproduces a “brain-like” pattern of MBNL ex-
pression, reverses the mis-splicing of Tau exon 2 when co-transfected
with the DT960 vector. This conﬁrms the essential role of MBNL2 in
brain function and splicing, as evidenced by enhanced Tau exon 2 skip-
ping in the brain of MBNL2 KOmice [19]. Interestingly, the rescue effect
induced by MBNL2 requires the presence of MBNL1. The effect of
MBNL2 alone is weak, whereasMBNL1 overexpression and silencing re-
spectively induce a clear increase or decrease of this rescue activity. The
fact that MBNL1 does not have its own rescue activity might be due to
the lack of endogenous MBNL2 expression in our cell system. Together
with the ﬁndings of Charizanis et al. [19], therefore, we propose that
the DM1 mutation induces a dual loss of MBNL1 and MBNL2,
which is sufﬁcient to lead to defective Tau exon 2 splicing, but the
presence of both MBNL1 and 2 is essential to completely reverse
the trans-dominant effect of the CUG repeats. In line with our previous
results suggesting that the C-terminal region ofMBNL1 could contribute
to its oligomerization [24], we speculate that hetero-oligomers con-
sisting of both MBNL1 and MBNL2 are necessary to restore normal
Tau splicing, whereas MBNL1 or MBNL2 alone is sufﬁcient for splicing-
enhancer activity but less effective at reversing the CUG repeat effect.
Interestingly, the dual silencing of MBNL1 and MBNL2 is similarly
more effective at reproducing the embryonic stem cell pattern of
FOXP1-ES splicing than the silencing of MBNL1 or MBNL2 alone [40].
In contrast, insulin receptor mis-splicing is rescued by either MBNL1
or MBNL2, with no additional effect of MBNL1 plus MBNL2 [39]. The
mechanisms involved are thus possibly related to the model used,
but our results suggest that the roles of MBNL paralogs should be
considered not only separately but also in combination, and that
RNA regulatory mechanisms driven by MBNL could differ in the
two cases.5. Conclusion
Our results clearly indicate that the CUG-inducedmis-splicing of Tau
exon 2 is mediated by a direct action of MBNL proteins at sites proximal
to the regulated exon. Both MBNL1 and 2 have enhancer activities with
regard to the splicing of Tau exon 2. However, ourmost unexpected and
striking ﬁnding concerns the cooperative effect of both MBNL1 and 2 in
the reversal of DM1-induced mis-splicing. Indeed, as far as Tau exon 2
splicing is concerned, bothMBNL2 andMBNL1 are necessary to fully re-
store the splicing of Tau exon 2, deregulated by the DM1mutation. This
result provides novel insights into the pathophysiology of DM1. We
therefore suggest that the trans-dominant effect of the DM1 mutation
is modulated both by the quantity and the number of MBNL paralogs
that are expressed in a given tissue. Our results raise the possibility
that speciﬁc splicing events could necessitate the recovery of both
MBNL2 andMBNL1 function, and ask whether this type of double regu-
lation speciﬁcally concerns the nervous system or not. In addition, our
ﬁndings support the development of future therapeutic strategies that
target a combination of bothmechanisms, and also indicate that Tau iso-
forms could be good diagnostic and therapeuticmarkers of the recovery
of MBNL1 and MBNL2 function in DM1.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.01.004.
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